

COVID-19 scenarios for the United States

IHME COVID-19 Forecasting Team

The United States (US) has not been spared in the ongoing pandemic of novel coronavirus disease^{1,2}. COVID-19, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to cause death and disease in all 50 states, as well as significant economic damage wrought by the non-pharmaceutical interventions (NPI) adopted in attempts to control transmission³. We use a deterministic, Susceptible, Exposed, Infectious, Recovered (SEIR) compartmental framework^{4,5} to model possible trajectories of SARS-CoV-2 infections and the impact of NPI⁶ at the state level. Model performance was tested against reported deaths from 01 February to 04 July 2020. Using this SEIR model and projections of critical driving covariates (pneumonia seasonality, mobility, testing rates, and mask use *per capita*), we assessed some possible futures of the COVID-19 pandemic from 05 July through 31 December 2020. We explored future scenarios that included feasible assumptions about NPIs including social distancing mandates (SDMs) and levels of mask use. The range of infection, death, and hospital demand outcomes revealed by these scenarios show that action taken during the summer of 2020 will have profound public health impacts through to the year end. Encouragingly, we find that an emphasis on universal mask use may be sufficient to ameliorate the worst effects of epidemic resurgences in many states. Masks may save as many as 102,795 (55,898–183,374) lives, when compared to a plausible reference scenario in December. In addition, widespread mask use may markedly reduce the need for more socially and economically deleterious SDMs.

22 The zoonotic origin of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)⁷ in
23 Wuhan, China⁸, and the global spread of the coronavirus disease (COVID-19)^{2,9} promises to be the
24 defining global health event of the twenty-first century. This pandemic has already resulted in extreme
25 societal, economic, and political disruption across the world and in the United States (US)^{3,10}. The
26 establishment of SARS-CoV-2 and its rapid spread in the US has been dramatic¹¹. Since the first case in
27 the US was identified on 20 January 2020¹² (first death on 06 February 2020¹³), SARS-CoV-2 has spread
28 to every state and resulted in more than 15.7 million cases and 127,868 deaths as of 4 July 2020¹⁴⁻¹⁶.

29 There remains no approved vaccine for the prevention of SARS-CoV-2 infection and few
30 pharmaceutical options for the treatment of the COVID-19 disease^{17,18}. The most optimistic
31 commentators do not predict the availability of new vaccines or therapeutics before 2021¹⁹. Non-
32 pharmaceutical interventions (NPI) are, therefore, the only available policy levers to reduce
33 transmission²⁰. Several such NPI have been put in place across the US in response to the epidemic (Fig.
34 1), including the dampening of transmission through the wearing of face masks and social distancing
35 mandates (SDM) aimed at reducing contacts through school closures, restrictions of gatherings, stay at
36 home orders, and the partial or full closure of non-essential businesses. Increased testing and isolation
37 of infected individuals will also have had an impact⁶. These NPI are credited with a reduction in disease
38 transmission^{21,22}, along with a host of other hypotheses on environmental, behavioral, and social
39 determinants of the course of the epidemic at the state level.

40 In the US, decisions to impose SDM or require mask use are generally made at the state level by
41 government officials. These executives need to balance net losses from the societal turmoil, economic
42 damage, and indirect effects on health caused by NPI with the direct benefits to human health of
43 controlling the epidemic, all within a complex political environment. Control has usually been defined as
44 the restriction of infections to below a specified level at which health services are not overwhelmed by
45 demand and the loss of human health and life is minimized²³.

46 In the first stages of the SARS-CoV-2 outbreak in the US, states sequentially enacted increasingly
47 restrictive SDMs meant to reduce transmission (by reducing human-to-human contact)¹ at the same
48 time as there was conflicting advice on the use of masks by the general public²⁴. At that early stage,
49 relatively simple statistical models of future risk were sufficient to capture the general patterns of
50 transmission²⁵. As different behavioral responses to SDM began to emerge, and more importantly, as
51 some states began to remove SDM (Fig. 1), a modeling approach that directly quantifies transmission
52 and could be used to explore these developing scenarios was necessary²⁵. As states variously remove
53 and reinstate SDM (Fig. 1) or begin to issue mandatory mask use orders²⁶ amid resurgences of COVID-
54 19²⁷, there is an urgent need for evidence-based assessments of the likely impact of the NPI options
55 available to decision-makers.

56 There is now a growing consensus that face masks, whether cloth or medical-grade, can
57 considerably reduce the transmission of respiratory viruses like SARS-CoV2, thereby limiting spread of
58 COVID-19²⁸⁻³⁰. While medical-grade masks may provide enhanced protection, cloth face coverings
59 (homemade or manufactured), have been found to be comparably effective in non-medical settings²⁸, as
60 well as being simple, widely accessible, and available commonly at relatively low cost. We updated a
61 recently published review²⁸ to generate a novel meta-analysis (Supplementary Information section 3.4)
62 of both peer-reviewed studies and pre-prints to assess mask effectiveness at preventing respiratory viral
63 infections in humans³¹. This analysis suggested a reduction in infection (from all respiratory viruses) for
64 mask-wearers by one-third (Relative Risk = 0.65 (0.47-0.92)) relative to controls. This is suggestive of a
65 considerable population health benefit to mask wearing that may be particularly effective in the US,
66 where currently only 41.1% of Americans have reported always wearing a mask in public
67 (Supplementary Information section 3.4)³².

68 Here we provide a state-level descriptive epidemiological analysis of the introduction of SARS-
69 CoV-2 infection across the US, from the first recorded case, through to 04 July 2020. We use these

70 observations to learn about epidemic progression and thereby model the first wave of transmission
71 using a deterministic Susceptible, Exposed, Infectious, Recovered (SEIR) compartmental framework^{4,5}.
72 This observed, process-based understanding of how NPI affect epidemiological processes is then used to
73 make inferences about the future trajectory of COVID-19 and how different combinations of existing NPI
74 might affect this course. Three SEIR-driven scenarios, along with covariates that inform them, were then
75 projected until 31 December 2020 (see methods). We use these scenarios as a sequence of experiments
76 to describe a range of model outputs including $R_{effective}$ (the change over time in the average number
77 of secondary cases per infectious case in a population where not everyone is susceptible^{4,5,33}), infections,
78 deaths, and hospital demand outcomes which might be expected from plausible subsets of the policy
79 options applied in the summer and fall of 2020 (see methods, Supplementary Information section 6.1 for
80 more rationale on scenario construction and considerations).

81 Briefly, we forecast the expected outcomes if states continue to remove SDMs at the current
82 pace (“mandates easing”), with resulting increases in population mobility and number of contacts. This
83 is an alternative scenario to the more probable situation, where states are expected to respond to an
84 impending health crisis by re-imposing some SDMs. In that plausible reference scenario, we model the
85 future progress of the pandemic assuming that states would move to once again shut down social
86 interaction and economic activity at a threshold for the daily death rate; when 8 daily deaths per million
87 population is reached – the 90th percentile of the observed distribution of when states previously
88 implemented SDM (Fig. 1, Supplementary Information section 3) – we assume reinstatement of SDM for
89 six weeks. In addition, newly available data on mask efficacy enabled the exploration of a third,
90 “universal mask” scenario to investigate the potential population-level benefits of increased mask use in
91 addition to a threshold-driven reinstatement of SDM. In this scenario, “universal” was defined as 95% of
92 people wearing masks in public, based on the current highest rate of mask use globally (in Singapore),

93 during the COVID-19 pandemic to date (Supplementary Information section 3.4). All scenarios presume
94 an increase in mobility associated with the opening of schools across the country.

95 Observed COVID-19 trends

96 The COVID-19 epidemic has progressed unevenly across states. Since the first death was recorded in the
97 US in early February 2020, cumulative through 04 July 2020, 127,868 deaths from COVID-19 have been
98 reported in the US (Fig. 2); a quarter of those (24.5%) occurred in New York alone. Washington and
99 California issued the first sets of state-level mandates on 11 March that prohibited gatherings of 250
100 people or more in certain counties, and by 23 March, all 50 states initiated some combination of SDM
101 (Fig. 1). The highest levels of daily deaths at the state level between February and June of 2020 occurred
102 in New York, New Jersey, and Massachusetts at 935.3, 330.2, and 168.1 deaths per day (Fig. 3, Extended
103 Data Fig. 1). At the end of June, the highest level of daily deaths was in California at 73.5 deaths per day.
104 A critical policy need at this stage of the modeling was the forecasting of hospital demand in the US in
105 the states with the worst effective transmission rates (Hawaii, South Carolina, and Florida; Fig. 4). The
106 highest peak demand was observed as 5969 hospital ICU beds in New York on April 8 and 3073 ICU beds
107 in New Jersey on April 19; health care capacity was exceeded in 11 states (New York, New Jersey,
108 Connecticut, Massachusetts, Michigan, Maryland, Louisiana, Pennsylvania, Rhode Island, Delaware,
109 District of Columbia) (Extended Data Figs 2,3). Demand had receded to within capacity levels across the
110 US by the end of May.

111 Predicted COVID-19 trends

112 Under a scenario where states continue with planned removal of SDMs (“mandates easing”), our model
113 projects that cumulative total deaths across the US could reach 430,494 (288,046–649,582) by 31
114 December 2020 (Fig. 2, Table 1). At the state level, contributions to that death toll would not be evenly
115 distributed across the US. Greater than 60% of the deaths projected between July and December 2020

116 in this scenario would occur across just five states: California, Florida, Texas, Massachusetts, and
117 Virginia; the highest cumulative death rates (per 100,000) between July and December 2020 are
118 projected to occur in Massachusetts (465.0 (302.4–659.9) deaths per 100,000)), Florida (272.4 (117.3–
119 551.0) deaths per 100,000), Virginia (214.9 (78.4–468.8) deaths per 100,000), and New Jersey (207.2
120 (191.5–235.0) deaths per 100,000) (Extended Data Fig. 4, Table 1). By 03 November 2020 – when many
121 Americans may need to queue in public for national elections – a total of four states are predicted to
122 exceed a threshold of daily deaths of 8 deaths per million (Fig. 3), and a total of 41 states would have an
123 $R_{effective}$ greater than one (Fig. 4), presenting a possible increased risk of spread if preventive
124 measures are not taken at that time. By 31 December 2020, a total of 24 states are predicted to exceed
125 that threshold and 47 states would reach an $R_{effective}$ of greater than one before the end of the year
126 (Table 1; Fig. 4). This scenario results in an estimated total of 67,485,279 (41,003,799–101,794,827)
127 infections across the United States by the end of year (Extended Data Fig. 5). The highest infection levels
128 in states relative to their population are estimated to occur in Massachusetts (58.0% (39.9–74.9%)
129 infected), Virginia (37.5% (13.8–68.0%) infected), and Washington (37.1% (15.0–67.0%) infected)
130 (Extended Data Fig. 6). Further results for hospital resource use needs are presented in Extended Data
131 Figs 2,3 and forecast infections under this scenario are presented in Extended Data Figs 7,8.

132 When we model the future course of the epidemic assuming that states will move to once again
133 shut down social interaction and economic activity when daily deaths reach a threshold of 8 deaths per
134 million (the plausible “reference” scenario), the projected cumulative death toll across the US is forecast
135 to be lower than under the “mandates easing” scenario, with 294,565 (233,885–398,397) deaths by 31
136 December 2020 (Fig. 2). Thus, across the 24 states that are projected to exceed 8 deaths per million
137 under the “mandates easing” scenario by the end of 2020 (Table 1), the re-imposition of SDM could save
138 135,929 (49,669–278,666) lives. This scenario results in 30,336,701 (12,044,797–55,506,392) fewer
139 estimated infections across the United States by the end of year (Extended Data Fig. 5) compared to the

140 “mandates easing” scenario, with the highest rates of infections estimated to occur in New Jersey
141 (24.9% (21.8–30.8%) infected), Massachusetts (21.2% (18.0–27.8%) infected), and Louisiana (19.4%
142 (12.6–33.8%) infected) (Extended Data Fig. 6). As with the previous scenario, even with the re-
143 imposition of SDM when daily deaths exceed 8 per million population, 47 states would reach an
144 $R_{effective}$ greater than one before the end of the year (Fig. 4, Table 1). Further results for hospital
145 resource use needs are presented in Extended Data Figs 2,3 and forecast infections under this scenario
146 are presented in Extended Data Figs 7,8.

147 The scenario where the population of each state was assumed to adopt and maintain the
148 maximum observed level of mask use observed globally (see methods) – in addition to states re-
149 imposing SDM if a threshold daily death rate of 8 deaths per million population was exceeded – resulted
150 in the lowest projected cumulative death toll across US states, with a total of 191,771 (175,160–
151 223,377) deaths forecast to occur by 31 December 2020 (Fig. 2, Table 1). Under this scenario, at the time
152 of the US national election on 3 November 2020, no states will have exceeded a daily death rate of 8
153 deaths per million (Fig. 3), although 38 states are still estimated to exceed an $R_{effective}$ of one at some
154 point between 4 July and 31 December 2020, and 33 states would have an $R_{effective}$ greater than one
155 on 31 December (Fig. 4). Through the end of the year, the daily death rate is forecast to exceed 8 deaths
156 per million in just three states (California, Massachusetts, and Virginia) (Table 1) saving 102,795
157 (55,898–183,374) lives when compared to the plausible reference scenario and 238,723 (112,886–
158 426,205) lives when compared to the “mandates easing” scenario. Universal mask use combined with
159 threshold-driven imposition of SDM results in 12,920,928 (7,136,980–22,826,322) fewer estimated
160 infections across the United States by the end of year compared to the plausible reference scenario, and
161 43,257,629 (19,744,352–74,125,020) fewer estimated infections compared to the “mandates easing”
162 scenario (Extended Data Fig. 5). The highest infection rates under the mask use scenario are estimated
163 to occur in Massachusetts (21.0% (17.3–29.9%) infected), New Jersey (20.7% (19.3–22.5%) infected),

164 and New York (17.8% (16.8–18.7%) infected) (Extended Data Fig. 6). Further results for hospital resource
165 use needs are presented in Extended Data Figs 2,3 and forecast infections under this scenario are
166 presented in Extended Data Figs 7,8.

167 Discussion

168 We delimit three possible futures (continued removal of SDM, plausible reference, and universal mask-
169 use scenarios), to help frame and inform a national discussion on what actions can be taken during the
170 summer of 2020 and the profound public health, economic, and political influences these decisions will
171 have for the rest of the year. Under all scenarios, the US is likely to face a continued public health
172 challenge from the COVID-19 pandemic through December 2020 and beyond, with populous states in
173 particular facing high levels of illness, deaths, and hospital demands from the disease. The
174 implementation of SDMs as soon as individual states reach a threshold of 8 daily deaths per million can
175 dramatically ameliorate the effects of the disease; achieving near universal mask use could delay or
176 prevent this threshold from being reached in many states and has the potential to save the most lives
177 while minimizing damage to the economy. National and state-level decision makers can use these
178 forecasts of the potential health benefits of available NPI alongside considerations of economic and
179 other social costs to make the most informed decisions on how to confront the COVID-19 pandemic at
180 the local level. Our findings indicate that mask use, a relatively affordable and low-impact intervention,
181 has the potential to serve as a priority life-saving strategy in all US locations.

182 New epidemics, resurgences, and second waves are not inevitable. Several countries have
183 sustained reductions in COVID-19 cases over time³². Early indications that seasonality may play a role in
184 transmission, with increased spread during colder winter months as is seen with other respiratory
185 viruses^{34–37}, highlight the importance of taking action both before and during the pneumonia season in
186 the US. While it is yet unclear if COVID-19 seasonality will match that of pneumonia in general, the

187 strong association observed so far should be heeded as a plausible warning of what is to come. Toward
188 the end of 2020, masks could contain a second wave of resurgence while reducing the need for frequent
189 and widespread imposition of SDMs. Such an approach has the potential to save lives while minimizing
190 the economic and societal disruption associated with both restrictive SDMs and the pandemic itself.
191 Although 95% mask use across the population may seem like a high threshold to achieve and maintain,
192 this value represents a level that has been achieved elsewhere (see methods and Supplementary
193 Information section 3.4). Where mask use has been widely adopted, in South Korea, Hong Kong, Japan,
194 and Iceland, among others, transmission has declined and in some cases halted³². These examples serve
195 as additional natural experiments³⁸ of the likely impact of masks and support the findings from the
196 universal mask use scenario. Long-term, the future of COVID-19 in the US will be determined by the
197 evolution of herd immunity through progressive pandemic waves over seasons and/or through the
198 deployment of an efficacious vaccine or therapeutic approaches.

199 Mask use has emerged as a contentious issue in the US. At the same time, although well below
200 the rates seen in other countries, about 41% of US residents have reported that they “always” wear a
201 mask³¹. The highest proportions of mask use were reported in the northeast of the country, where
202 several states had estimated mask use greater than 60% on 26 June 2020³¹. The potential life-saving
203 benefit of increasing mask use in the coming summer and fall cannot be overstated. Recent large-scale
204 outdoor gatherings, such as the massive marches and protests against police brutality and racism that
205 took place in June 2020 in the US, seem to have had a negligible effect on SARS-CoV-2 infection rates³⁹
206 possibly due to high levels of mask use⁴⁰. As Americans prepare to head to the polls in November, local
207 policy makers should consider the health implications of long lines at polling places and the role of mask
208 use (or alternatives such as mail-in voting) in mitigating disease spread. Several states have already
209 postponed primary elections in an effort to avoid increased transmission. Mandatory mask laws have
210 also been introduced in many states^{38,41}, but compliance appears to be variable, indicating that

211 mandates alone may be insufficient to substantially alter behavior. In certain locations, such as prisons,
212 mask use alone may not be sufficient to prevent transmission, social distancing may not be feasible, and
213 alternate solutions to protect these vulnerable populations may be needed⁴². Ultimately, US residents
214 will need to choose between higher levels of mask use or risking the frequent redeployment of more
215 stringent and economically damaging SDMs; or, in the absence of either measure, face a reality of a
216 rising death toll⁴³.

217 This work represents the outputs of a class of models that aim to abstract the disease
218 transmission process in populations to a level that is tractable for understanding, and, in this case, that
219 can be used for predictions. A clear consequence of any such exercise is that it will be limited by data
220 (disease and relevant covariates), the model of understanding developed, and the length of time
221 available to the model to learn/train the important dynamics. We have therefore tried to benchmark
222 our model against alternative models of the COVID-19 pandemic and fully document our predictive
223 performance with a range of measures⁴⁴. In addition, we have provided the reader all the data and
224 model code to enable full reproducibility and increased transparency and presented a range of likely
225 futures in the form of a continued removal of mandates, plausible reference, and universal mask use
226 scenario for decision makers to review. In addition, triangulation of other outputs of the SEIR model,
227 such as the proportion of the population that are affected, are also provided and tested against
228 independent data, in this case seroprevalence surveys (Extended Data Fig. 9). Finally, because
229 uncertainty compounds with distance into the future predicted, the data, model, and its assumptions
230 will be iteratively updated as the pandemic continues to unfold.

231 As we extend this work to investigate the impact of mask use and other NPI on the global
232 pandemic, we are hopeful that masks will be sufficient in all states to avoid a COVID-19 resurgence in
233 the US and avoid further economic damage. The US can reduce a potential second wave, if its residents
234 decide to do so.

235 Online content

236 Results for each state are accessible through a visualization tool at <http://covid19.healthdata.org>. The
237 estimates presented in this tool will be iteratively updated as new data are incorporated and will
238 ultimately supersede the results in this paper.

239

240 References

- 241 1. Miller, I. F., Becker, A. D., Grenfell, B. T. & Metcalf, C. J. E. Disease and healthcare burden of COVID-
242 19 in the United States. *Nat. Med.* 1–6 (2020) doi:10.1038/s41591-020-0952-y.
- 243 2. World Health Organization. *Coronavirus disease 2019 (COVID-19) situation report 163*.
244 [https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200701-covid-19-](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200701-covid-19-sitrep-163.pdf?sfvrsn=c202f05b_2)
245 [sitrep-163.pdf?sfvrsn=c202f05b_2](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200701-covid-19-sitrep-163.pdf?sfvrsn=c202f05b_2) (2020).
- 246 3. Chetty, R., Friedman, J. N., Hendren, N., Stepner, M. & The Opportunity Insights Team. How did
247 COVID-19 and stabilization policies affect spending and employment? A new real-time economic
248 tracker based on private sector data. (2020).
- 249 4. Bjørnstad, O. N., Shea, K., Krzywinski, M. & Altman, N. The SEIRS model for infectious disease
250 dynamics. *Nat. Methods* **17**, 557–558 (2020).
- 251 5. Bjørnstad, O. N., Shea, K., Krzywinski, M. & Altman, N. Modeling infectious epidemics. *Nat. Methods*
252 **17**, 455–456 (2020).
- 253 6. Peak, C. M., Childs, L. M., Grad, Y. H. & Buckee, C. O. Comparing nonpharmaceutical interventions
254 for containing emerging epidemics. *Proc. Natl. Acad. Sci.* **114**, 4023–4028 (2017).
- 255 7. Andersen, K. G., Rambaut, A., Lipkin, W. I., Holmes, E. C. & Garry, R. F. The proximal origin of SARS-
256 CoV-2. *Nat. Med.* **26**, 450–452 (2020).

- 257 8. World Health Organization. *Novel coronavirus disease (2019-nCoV) situation report 1*.
258 [https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf?sfvrsn=20a99c10_4)
259 [ncov.pdf?sfvrsn=20a99c10_4](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf?sfvrsn=20a99c10_4) (2020).
- 260 9. World Health Organization. WHO coronavirus disease (COVID-19) dashboard. *WHO Coronavirus*
261 *Disease (COVID-19) Dashboard* <https://covid19.who.int/> (2020).
- 262 10. Spluttering - Tracking the economic impact of covid-19 in real time. *The Economist*.
- 263 11. Council on Foreign Relations. Timeline of the coronavirus. *Think Global Health*
264 <https://www.thinkglobalhealth.org/article/updated-timeline-coronavirus> (2020).
- 265 12. Holshue, M. L. *et al.* First case of 2019 novel coronavirus in the United States. *N. Engl. J. Med.* **382**,
266 929–936 (2020).
- 267 13. County of Santa Clara Emergency Operations Center. County of Santa Clara identifies three
268 additional early COVID-19 deaths - Novel coronavirus (COVID-19). *Santa Clara County Public Health*
269 <https://www.sccgov.org/sites/covid19/Pages/press-release-04-21-20-early.aspx> (2020).
- 270 14. Xu, B. *et al.* Open access epidemiological data from the COVID-19 outbreak. *Lancet Infect. Dis.* **20**,
271 534 (2020).
- 272 15. Xu, B. *et al.* Epidemiological data from the COVID-19 outbreak, real-time case information. *Sci. Data*
273 **7**, 1–6 (2020).
- 274 16. Johns Hopkins University Center for Systems Science and Engineering. COVID-19 dashboard. *Johns*
275 *Hopkins Coronavirus Resource Center* <https://coronavirus.jhu.edu/map.html> (2020).
- 276 17. Beigel, J. H. *et al.* Remdesivir for the treatment of Covid-19 — Preliminary report. *N. Engl. J. Med.*
277 (2020) doi:10.1056/NEJMoa2007764.
- 278 18. Boulware, D. R. *et al.* A randomized trial of hydroxychloroquine as postexposure prophylaxis for
279 Covid-19. *N. Engl. J. Med.* (2020) doi:10.1056/NEJMoa2016638.

- 280 19. Callaway, E. Coronavirus vaccine trials have delivered their first results — but their promise is still
281 unclear. *Nature* **581**, 363–364 (2020).
- 282 20. Anderson, R. M., Heesterbeek, H., Klinkenberg, D. & Hollingsworth, T. D. How will country-based
283 mitigation measures influence the course of the COVID-19 epidemic? *The Lancet* **395**, 931–934
284 (2020).
- 285 21. Ngonghala, C. N. *et al.* Mathematical assessment of the impact of non-pharmaceutical interventions
286 on curtailing the 2019 novel coronavirus. *Math. Biosci.* **325**, 108364 (2020).
- 287 22. Lasry, A. Timing of community mitigation and changes in reported COVID-19 and community
288 mobility — Four U.S. metropolitan areas, February 26–April 1, 2020. *MMWR Morb. Mortal. Wkly.*
289 *Rep.* **69**, (2020).
- 290 23. McKee, M. & Stuckler, D. If the world fails to protect the economy, COVID-19 will damage health not
291 just now but also in the future. *Nat. Med.* **26**, 640–642 (2020).
- 292 24. Jingnan, H. Why there are so many different guidelines for face masks for the public. *NPR.org*.
- 293 25. IHME COVID-19 Forecasting Team. Predictive performance of international COVID-19 mortality
294 forecasting models. *Nature* **MS ID: 2020-06-10908.**, (2020).
- 295 26. Kim, A., Andrew, S. & Froio, J. These are the states requiring people to wear masks when out in
296 public. *CNN*.
- 297 27. U.S. reports nearly 50,000 new coronavirus cases, another single-day record. *The New York Times*
298 (2020).
- 299 28. Liang, M. *et al.* Efficacy of face mask in preventing respiratory virus transmission: A systematic
300 review and meta-analysis. *Travel Med. Infect. Dis.* 101751 (2020).
- 301 29. Leung, N. H. L. *et al.* Respiratory virus shedding in exhaled breath and efficacy of face masks. *Nat.*
302 *Med.* **26**, 676–680 (2020).

- 303 30. Chu, D. K. *et al.* Physical distancing, face masks, and eye protection to prevent person-to-person
304 transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. *The Lancet* **395**,
305 1973–1987 (2020).
- 306 31. Institute for Health Metrics and Evaluation. Technical briefing: Curbing the spread of COVID-19: The
307 effectiveness of face masks.
- 308 32. Institute for Health Metrics and Evaluation. COVID-19 projections. <https://covid19.healthdata.org/>.
- 309 33. Cintrón-Arias, A., Castillo-Chavez, C., Bettencourt, L. M. A., Lloyd, A. L. & Banks, H. T. The estimation
310 of the effective reproductive number from disease outbreak data. *Math. Biosci. Eng.* **6**, 261–282
311 (2009).
- 312 34. Wang, J., Tang, K., Feng, K. & Lv, W. High temperature and high humidity reduce the transmission of
313 COVID-19. *SSRN Electron. J.* (2020) doi:10.2139/ssrn.3551767.
- 314 35. Kissler, S. M., Tedijanto, C., Goldstein, E., Grad, Y. H. & Lipsitch, M. Projecting the transmission
315 dynamics of SARS-CoV-2 through the postpandemic period. *Science* **368**, 860–868 (2020).
- 316 36. Killerby, M. E. *et al.* Human coronavirus circulation in the United States 2014–2017. *J. Clin. Virol.*
317 **101**, 52–56 (2018).
- 318 37. Shaman, J., Pitzer, V. E., Viboud, C., Grenfell, B. T. & Lipsitch, M. Absolute humidity and the seasonal
319 onset of influenza in the continental United States. *PLOS Biol.* **8**, e1000316 (2010).
- 320 38. Lyu, W. & Wehby, G. L. Community use of face masks and COVID-19: Evidence from a natural
321 experiment of state mandates in the US. *Health Aff. (Millwood)* 10.1377/hlthaff.2020.00818 (2020)
322 doi:10.1377/hlthaff.2020.00818.
- 323 39. Dave, D., Friedson, A., Matsuzawa, K., Sabia, J. & Safford, S. *Black lives matter protests, social*
324 *distancing, and COVID-19.* w27408 <http://www.nber.org/papers/w27408.pdf> (2020)
325 doi:10.3386/w27408.
- 326 40. Silva, C. Parties — not protests — are causing spikes In Coronavirus. *NPR.org*.

- 327 41. Littler Mendelson & 2020. Facing your face mask duties – A list of statewide orders, as of June 26,
328 2020. *Littler Mendelson P.C.* <https://www.littler.com/publication-press/publication/facing-your->
329 [face-mask-duties-list-statewide-orders](https://www.littler.com/publication-press/publication/facing-your-face-mask-duties-list-statewide-orders) (2020).
- 330 42. Malloy, G. S., Puglisi, L., Brandeau, M. L., Harvey, T. D. & Wang, E. A. The effectiveness of
331 interventions to reduce COVID-19 transmission in a large urban jail. *medRxiv* (2020).
- 332 43. López, L. & Rodó, X. The end of social confinement and COVID-19 re-emergence risk. *Nat. Hum.*
333 *Behav.* 1–10 (2020) doi:10.1038/s41562-020-0908-8.
- 334 44. Flaxman, S. *et al.* Estimating the effects of non-pharmaceutical interventions on COVID-19 in
335 Europe. *Nature* 1–8 (2020) doi:10.1038/s41586-020-2405-7.
- 336

337 Figure legends

338 **Figure 1.** Number of social distancing mandates by state in the US on a timeline starting on 01 February 2020
339 through to 04 July 2020. States are ordered by decreasing population size on the y-axis.

340 **Figure 2.** Cumulative deaths from 01 February to 31 December 2020. The inset map displays the cumulative deaths
341 under the “plausible reference” scenario on 31 December 2020. A light yellow background separates the observed
342 and predicted part of the time series, before and after 04 July. The dashed vertical line identifies 03 November
343 2020. The red line is the “mandates easing” scenario, the purple line the “plausible reference” scenario, and the
344 green line the “universal mask” scenario. Numbers are the means and UIs for the plausible reference scenario on
345 dates highlighted. The UIs are not shown for the “mandates easing” and “universal mask” scenarios for clarity.
346 State panels are ordered by decreasing population size. Two-letter state abbreviations are provided in panels and
347 the inset map. An asterisk next to state abbreviation indicates a state with one or more urban agglomerations
348 exceeding two million persons. State panels are scaled to accommodate the state with the highest value (CA here),
349 and range from zero to 68,000 cumulative deaths. This map was generated with R Studio (R Version 3.6.3).

350 **Figure 3.** Daily deaths from 01 February to 31 December 2020. The inset map displays the daily deaths under the
351 “plausible reference” scenario on 31 December 2020. A light yellow background separates the observed and
352 predicted part of the time series, before and after 04 July. The dashed vertical line identifies 03 November 2020.
353 The red line is the “mandates easing” scenario, the purple line the “plausible reference” scenario, and the green
354 line the “universal mask” scenario. Numbers are the means and UIs for the plausible reference scenario on dates
355 highlighted. The UIs are not shown for the “mandates easing” and “universal mask” scenarios for clarity. State
356 panels are ordered by decreasing population size. Two-letter state abbreviations are provided in panels and the
357 inset map. An asterisk next to state abbreviation indicates a state with one or more urban agglomerations
358 exceeding two million persons. State panels are scaled to accommodate the state with the highest value (CA here),
359 and range from zero to 2,500 daily deaths. This map was generated with R Studio (R Version 3.6.3).

360 **Figure 4.** Time series for values of $R_{\text{effective}}$ by state in the US. Inset maps display the value of $R_{\text{effective}}$ on 03
361 November and 31 December 2020; time series of $R_{\text{effective}}$ are presented for each state as separate panels. A light
362 yellow background separates the observed and predicted part of the time series, before and after 04 July. The
363 dashed vertical line identifies 03 November 2020. The red line is the “mandates easing” scenario, the purple line
364 the “plausible reference” scenario, and the green line the “universal mask” scenario. The UIs are not shown for the
365 “mandates easing” and “universal mask” scenarios for clarity. State panels are ordered by decreasing population
366 size. Two-letter state abbreviations are provided in panels and the inset maps. An asterisk next to state
367 abbreviation indicates a state with one or more urban agglomerations exceeding two million persons. For legibility
368 purposes, the y-axes of the state panels are displayed from 0.25 to 4 and the x-axes from 01 March to 31
369 December 2020. These maps were generated with R Studio (R Version 3.6.3).

370 **Table 1.** Cumulative deaths 04 July 2020 through 31 December 2020, maximum estimated daily deaths per million
371 population, date of maximum daily deaths, and estimated $R_{\text{effective}}$ on 31 December 2020 for three scenarios.

372

373

374 Methods

375 Our analysis strategy supports two main and interconnected objectives: (1) generate predictions of
376 COVID-19 deaths, infections, and hospital resource needs for all US states; and (2) explore alternative
377 scenarios on the basis of changes in state-imposed social distancing mandates or population levels of
378 mask use. The modeling approach to achieve this is summarized in Supplementary Information section 2
379 and can be divided into four stages: (1) identification and processing of COVID-19 data, (2) exploration
380 and selection of key drivers or covariates, (3) modelling deaths and cases across three scenarios of SDM
381 in US states using an SEIR framework, and (4) modeling health service utilization as a function of forecast
382 infections and deaths within those scenarios. This study complies with the Guidelines for Accurate and
383 Transparent Health Estimates Reporting (GATHER) statement (Supplementary Information).

384

385 Data identification and processing

386 IHME forecasts include data from local and national governments, hospital networks and associations,
387 the World Health Organization, third-party aggregators, and a range of other sources. Data sources and
388 corrections are described in detail in the Supplementary Information. Briefly, daily confirmed case and
389 death numbers due to COVID-19 are collated from the Johns Hopkins University (JHU) data repository;
390 we supplement and correct this dataset as needed to improve the accuracy of our projections and
391 adjust for reporting-day biases (see Supplementary Information Table 4). Testing data are obtained from
392 the *Our World in Data* COVID tracking project and supplemented with data from additional government
393 websites (Supplementary Information Table 8). Social distancing data are obtained from a number of
394 different official and open sources, which vary by state (Supplementary Information Table 7). Mobility
395 data are obtained from Facebook Data for Good, Google, SafeGraph, and Descartes Labs
396 (Supplementary Information section 3.2). Mask use data are obtained from the Facebook Global
397 Symptom Survey (in collaboration with the University of Maryland Social Data Science Center) and

398 PREMISE (Supplementary Information section 3.4). Specific sources for data on licensed bed and ICU
399 capacity and average annual utilization in the United States are detailed in the Supplementary
400 Information section 2.

401 Before modeling, observed cumulative deaths are smoothed using a spline-based smoothing
402 algorithm with randomly placed knots. Uncertainty is derived from bootstrapping and resampling of the
403 observed deaths. The time series of case data is used as a leading indicator of death based on an
404 infection fatality ratio (IFR) and a lag from infection to death. These smoothed estimates of observed
405 deaths by location are then used to create estimated infections based on an age-distribution of
406 infections and on age-specific IFRs. The age-specific infections were collapsed into total infections by day
407 and state and used as data inputs in the SEIR model. Detailed descriptions of data smoothing and
408 transformation steps are provided in the Supplementary Information.

409

410 Covariate selection

411 Covariates for the compartmental transmission SEIR model are predictors of the β parameter in the
412 model that affects the transition from Susceptible to Exposed state. Covariates were evaluated on the
413 basis of biologic plausibility and on the impact on the results of the SEIR model. Given limited empirical
414 evidence of population-level predictors of SARS-CoV-2 transmission, biologically plausible predictors of
415 pneumonia such as population density (percentage of the population living in areas with more than
416 1000 individuals per square kilometer), tobacco smoking prevalence, population-weighted elevation,
417 lower respiratory infection mortality rate, and particulate matter air pollution were considered. These
418 covariates are representative at a population level and are time-invariant. Spatially resolved estimates
419 for these covariates are derived from the Global Burden of Disease Study 2019⁴⁵. Time-varying
420 covariates include pneumonia excess mortality seasonality, diagnostic tests per capita, population-level
421 mobility, and personal mask use. These are described in the following sections.

422 **Pneumonia seasonality**

423 We used weekly pneumonia mortality data from the National Center for Health Statistics Mortality
424 Surveillance System⁴⁶ from 2013 to 2019 by US state. Pneumonia deaths included all deaths classified by
425 the full range of ICD codes in J12–J18.9. We pooled data over available years for each state and found
426 the weekly deviation from the annual, state-specific mean mortality due to pneumonia. We then fit a
427 seasonal pattern using a Bayesian meta-regression model with a flexible spline and assumed annual
428 periodicity (Supplementary Information section 3.5). For locations outside the United States, we used
429 vital registration data where available. Locations without vital registration data had weekly pneumonia
430 seasonality predicted based on latitude from a model pooling all available data (Supplementary
431 Information section 3.5).

432

433 **Testing per capita**

434 We considered diagnostic testing for active SARS-CoV-2 infections as a predictor of the ability for a state
435 to identify and isolate active infections. We assumed that higher rates of testing are negatively
436 associated with SARS-CoV-2 transmission. Our primary sources for US testing data were compiled by the
437 COVID Tracking Project (Supplementary Information section 3.3 and SI Table 8). Unless testing data
438 existed before the first confirmed case in a state, we assumed that testing is non-zero after the date of
439 the first confirmed case. Before producing predictions of testing per capita, we smoothed the input data
440 by using the same smoothing algorithm used for smoothing daily death data prior to modeling
441 (previously described). Testing per capita projections for unobserved future days were based on linearly
442 extrapolating the mean day-over-day difference in daily tests per capita for each location. We put an
443 upper limit on diagnostic tests per capita of 500 per 100,000 based on the highest observed rates in
444 June 2020.

445

446 Social distancing mandates

447 Social distancing mandates (SDMs) were not used as direct covariates in the transmission model. Rather,
448 SDMs were used to predict population mobility (see below) which is subsequently used as a covariate in
449 the transmission model. We collected the dates of state-issued mandates enforcing social distancing as
450 well as the planned or actual removal of these mandates. The measures that we included in our model
451 were 1) severe travel restrictions, 2) closing of public educational facilities, 3) closure of non-essential
452 businesses, 4) stay at home orders, 5) restrictions on gathering size. Generally, these came from state
453 government official orders or press releases.

454 To determine the expected change in mobility due to social distancing mandates, we used a
455 Bayesian, hierarchical meta-regression model with random effects by location on the composite mobility
456 indicator to estimate the effects of social distancing policies on changes in mobility (Supplementary
457 Information section 3.1).

458

459 Mobility

460 We used four data sources on human mobility to construct a composite mobility indicator. Those
461 sources were Facebook, Google, SafeGraph, and Descartes Labs (Supplementary Information section
462 3.2). Each source has a slightly different way of capturing mobility, so before constructing a composite
463 mobility indicator, we standardized these different data sources (Supplementary Information section
464 3.2). Briefly, this first involved determining the change in a baseline level of mobility for each location by
465 data source. Then, we determined a location-specific median ratio of change in mobility for each
466 pairwise comparison of mobility sources, using Google as a reference and adjusting the other sources by
467 that ratio. The time series for mobility was estimated using a Gaussian process regression model using
468 the standardized data sources to get a composite indicator for change in mobility for each location-day.

469 We calculated the residuals between our predicted composite mobility time series and input
470 composite time series, and then applied a first-order random walk to the residuals. The random walk

471 was used to predict residuals from 01 January 2020 to 01 January 2021, which were then added to the
472 mobility predictions to produce a final time series with uncertainty: “past” changes in mobility from 01
473 January 2020 to 27 June 2020, and projected mobility from 27 June 2020 to 01 January 2021.

474

475 **Masks**

476 We performed a meta-analysis of 40 peer-reviewed scientific studies in an assessment of mask
477 effectiveness for preventing respiratory viral infections (Supplementary Information section 3.4). The
478 studies were extracted from a preprint publication²⁸. In addition, we considered all articles from a
479 second meta-analysis³⁰ and one supplemental publication⁴⁷. These studies included both persons
480 working in health care and the general population – especially family members of those with known
481 infections. The studies indicate overall reductions in infections due to masks preventing exhalation of
482 respiratory droplets containing viruses, as well as some prevention of inhalation by those uninfected.
483 The resulting meta-regression calculated log-transformed relative risks and corresponding log-
484 transformed standard errors based on raw counts and used a continuity correction for studies with zero
485 counts in the raw data (0.001). Whereas the other meta-analyses reported one outcome per study, we
486 extracted all relevant outcomes per study. Additionally, we included additional specifications and
487 characteristics to account for differences in characteristics of individual studies and to identify important
488 factors impacting mask effectiveness. These include the type of population using masks (general
489 population versus health care population), country of study (Asian countries versus non-Asian
490 countries), type of mask (paper, cloth, or non-descript masks versus medical masks and N95 masks),
491 type of control group (no use versus infrequent use), type of disease (SARS-CoV 1 or 2 versus H1N1,
492 influenza, or other respiratory pathogens), and type of diagnosis (clinical versus laboratory).

493 We used MR-BRT – a meta-regression tool developed at the Institute for Health Metrics and
494 Evaluation (meta-regression, Bayesian, regularized, trimmed) (Supplementary Information section 2.5) –

495 to perform a meta-analysis that considered the various characteristics of each study. We accounted for
496 between-study heterogeneity and quantified remaining between-study heterogeneity into the width of
497 the uncertainty interval. We also performed various sensitivity analyses to verify the robustness of the
498 modeled estimates and found that the estimate of the effectiveness of mask use did not change
499 significantly when we explored four alternative analyses, including changing the continuity correction
500 assumption, using odds ratio versus relative risk from published studies, using a fixed effects versus a
501 mixed effects model, and including studies without covariate information.

502 We estimated the proportion of people who self-reported always wearing a face mask when
503 outside in public for both US and global locations using data from PREMISE (US) and Facebook (non-US).
504 We again used the same smoothing model as for COVID-19 deaths and testing per capita to produce
505 estimates of observed mask use. This smoothing process averaged each data point with its neighbors.
506 Tails are an average of the change in mask use over the three following days (left tail) and three
507 preceding days (right tail). The level of mask use starting on 26 June 2020 (or the last day of processed
508 and analyzed data) is assumed to be flat. Among states without state-specific data, a regional average
509 was used.

510 **Deterministic modeling framework**

511 Model specification is provided in detail in the Supplementary Information and summarized in a
512 schematic (SI Fig. 1). In order to fit and predict disease transmission dynamics, we include a susceptible-
513 exposed-infected-recovered (SEIR) component in our multi-stage model. In particular, each location's
514 population is tracked through the following system of differential equations:

$$\begin{aligned}\frac{dS}{dt} &= -\beta(t) \frac{S(I_1 + I_2)^\alpha}{N} \\ \frac{dE}{dt} &= \beta(t) \frac{S(I_1 + I_2)^\alpha}{N} - \sigma E\end{aligned}$$

$$\begin{aligned}\frac{dI_1}{dt} &= \sigma E - \gamma_1 I_1 \\ \frac{dI_2}{dt} &= \gamma_1 I_1 - \gamma_2 I_2 \\ \frac{dR}{dt} &= \gamma_2 I_2\end{aligned}$$

515 where α represents a mixing coefficient to account for imperfect mixing within each location, σ is the
516 rate at which infected individuals become infectious, γ_1 is the rate at which infectious people transition
517 out of the pre-symptomatic phase, and γ_2 is the rate at which individuals recover. This model does not
518 distinguish between symptomatic and asymptomatic infections but has two infectious compartments (I_1
519 and I_2) to allow for interventions that would avoid focus on those who could not be symptomatic; I_1 is
520 thus the pre-symptomatic compartment.

521 Using the next-generation matrix approach, we can directly calculate both the basic reproductive
522 number under control ($R_c(t)$) and the effective reproductive number ($R_{effective}(t)$) as (see
523 Supplementary Information section 5.1 for derivation):

$$R_c(t) = \alpha \cdot \beta(t) \cdot (I_1(t) + I_2(t))^{\alpha-1} * \left(\frac{1}{\gamma_1} + \frac{1}{\gamma_2} \right)$$

524 and

$$R_{effective}(t) = R_c(t) \cdot \frac{S(t)}{N}$$

525
526 By allowing $\beta(t)$ to vary in time, our model is able to account for increases in transmission intensity as
527 human behavior shifts over time (e.g., changes in mobility, adding or removing SDM, changes in
528 population mask use). Briefly, we combine data on cases (correcting for trends in testing),
529 hospitalizations, and deaths into a distribution of trends in daily deaths.

530 To fit this model, we resample 1000 draws of daily deaths from this distribution for each state
531 (see Supplementary Information section 5). Using an estimated IFR by age (Supplementary Information
532 section 4.2) and the distribution of time from infection to death (Supplementary Information section

533 4.3), we then use the daily deaths to generate 1000 distributions of estimated infections by day from 10
534 January to 04 July 2020. We then fit the rates at which infectious individuals may come into contact and
535 infect susceptible individuals (denoted as $\beta(t)$) as a function of a number of predictors that affect
536 transmission. Our modeling approach acts across the overall population (i.e., no assumed age structure
537 for transmission dynamics), and each location is modeled independently of the others (i.e., we do not
538 account for potential movement between locations).

539 We detail the SEIR fitting algorithm in the Supplementary Information section 5.1, but in brief,
540 by draw we first fit a smooth curve to our estimates of daily new infections. Then, sampling γ_2 , σ , and α
541 from defined ranges from literature (see SI) and using $\gamma_1 = \frac{1}{2}$, we then sequentially fit the E , I_1 , I_2 , and
542 R components in the past. We then algebraically solve the above system of differential equations for
543 $\beta(t)$.

544 The next stage of our model fits relationships between past changes in $\beta(t)$ and covariates
545 described above: mobility, testing, masks, pneumonia seasonality, others. As detailed in Supplementary
546 Information section 3, the time-varying covariates are forecast from 01 July to 31 December 2020. The
547 fitted regression is then used to estimate future transmission intensity $\beta_{pred}(t)$. The final future
548 transmission intensity is then an adjusted version of $\beta_{pred}(t)$ based on the average fit over the recent
549 past (where the window of averaging varies by draw from 2 to 4 weeks; see Supplementary Information
550 section 5 for more details).

551 Finally, we use the future estimated transmission intensity to predict future transmission (using,
552 for each draw, the same parameter values for all other SEIR parameters). In a reversal of the translation
553 of deaths into infections, we then use the estimated daily new infections to calculate estimated daily
554 deaths (again using the location-specific IFR). We also use the estimated trajectories of each SEIR
555 compartment to calculate R_c and $R_{effective}$.

556 A final step to take predicted infections and deaths and a hospital use microsimulation to
557 estimate hospital resource need for each US state is described in greater detail in the Supplementary
558 Information section 7 and the results presented online ([https://covid19.healthdata.org/united-states-of-](https://covid19.healthdata.org/united-states-of-america)
559 [america](https://covid19.healthdata.org/united-states-of-america)).

560 **Forecasts/scenarios**

561 Policy responses to COVID-19 can be supported by the evaluation of impacts of various scenarios of
562 those options, against a background of business as usual assumption, to explore fully the potential
563 impact of policy levers available.

564 We estimate the trajectory of the epidemic by state under a “mandates easing” scenario that
565 models what would happen in each state if the current pattern of easing social distancing mandates
566 continues and new mandates are not imposed. This should be thought of as a worst-case scenario,
567 where regardless of how high the daily death rate gets, SDM will not be re-introduced and behavior
568 (including population mobility and mask use) will not vary before 31 December 2020. In locations where
569 the number of cases is rising, this leads to very high predictions by the end of the year.

570 As a more plausible scenario, we use the observed experience from the first phase of the
571 pandemic to predict the likely response of state and local governments during the second phase. This
572 plausible reference scenario assumes that in each location the trend of easing SDM will continue at its
573 current trajectory until the daily death rate reaches a threshold of 8 deaths per million. If the daily death
574 rate in a location exceeds that threshold, we assume that SDM will be reintroduced for a six-week
575 period. The choice of threshold (of a rate of daily deaths of 8 per million) represents the 90th percentile
576 of the distribution of daily death rate at which US states implemented their mandates during the first
577 months of the COVID-19 pandemic. We selected the 90th percentile rather than the 50th percentile to
578 capture an anticipated increased reluctance from governments to re-impose mandates because of the
579 economic effects of the first set of mandates. In locations that do not exceed the threshold of a daily

580 death rate of 8 per million, the projection is based on the covariates in model and the forecasts for these
581 to 31 December 2020. In locations where the daily death rate exceeded 8 per million at the time of our
582 final model run for this manuscript (04 July 2020), we are assuming that mandates will be introduced
583 within seven days.

584 The scenario of universal mask wearing models what would happen if 95% of the population in
585 each state always wore a mask when they were in public. This value was chosen to represent the highest
586 observed rate of mask use in the world so far during the COVID-19 pandemic (see Supplementary
587 Information section 3.4). In this scenario, we also assume that if the daily death rate in a state exceeds 8
588 deaths per million, SDMs will be reintroduced for a six-week period.

589

590 Model validation

591 Model performance was tested against reported deaths from 01 February to 30 June 2020²⁴. Out-of-
592 sample predictive validity was assessed periodically for all model versions against subsequently
593 observed trends in COVID-19 weekly and cumulative mortality. The IHME hybrid SEIR model described
594 here was found to have a median absolute percent error of 9.9% at four weeks after the last available
595 input data²⁵. This work provides a comprehensive and reproducible platform for testing model
596 performance for the model presented here and all other models that have published and archived
597 similar predictions.

598 The increasing number of population-based serology surveys conducted also provide a unique
599 opportunity to cross-validate our prior predictions with modeled epidemiological outcomes. In Extended
600 Data Fig. 9 we compare these serology surveys (such as the Spanish ENE-COVID study⁴⁸) to our
601 estimated population seropositivity time-indexed to the date that the survey was conducted. In general,
602 across the varied locations that have been reported globally, we note a high degree of agreement

603 between the estimated and surveyed seropositivity. As more serology studies are conducted and
604 published, especially in the US, this will allow an ongoing and iterative assessment of model validity.

605

606 Limitations

607 Epidemics progress based on complex non-linear and dynamic biological and social processes that are
608 difficult to observe directly and at scale. Mechanistic models of epidemics, formulated either as ordinary
609 differential equations or as individual-based simulation models, are a useful tool for conceptualizing,
610 analyzing, or forecasting the time course of epidemics. In the COVID-19 epidemic, effective policies and
611 the responses to those policies have changed the conditions supporting transmission from one week to
612 the next, with the effects of policies realized typically after a variable time lag. Each model approximates
613 an epidemic, and whether used to understand, forecast, or advise, there are limitations on the quality
614 and availability of the data used to inform it and the simplifications chosen in model specification. It is
615 unreasonable to expect any model to do everything well, so each model makes compromises to serve a
616 purpose, while maintaining computational tractability.

617 One of the largest determinants of the quality of a model is the corresponding quality of the input
618 data. Our model is anchored to daily COVID-19-related deaths, as opposed to daily COVID-19 case
619 counts, due to the assumption that death counts are a less biased estimate of true COVID-19-related
620 deaths than COVID-19 case counts are of the true number of SARS-CoV-2 infections. Numerous biases
621 such as treatment-seeking behavior, testing protocols (such as only testing those who have traveled
622 abroad), and differential access to care greatly influence the utility of case count data. Moreover, there
623 is growing evidence that inapparent and asymptomatic individuals are infectious as well as individuals
624 who eventually become symptomatic being infectious before the onset of any symptoms. As such, our
625 primary input data for our model are counts of deaths; death data can likewise be fallible, however, and

626 where available, we combine death data, case data, and hospitalization data together to estimate
627 COVID-19 deaths.

628 Beyond the basic input data, there are a large number of other data sources with their own
629 potential biases that are incorporated into our model. Testing, mobility, and mask use are all imperfectly
630 measured and may or may not be representative of the practices of those that are susceptible and/or
631 infectious. Moreover, any forecast of the patterns of these covariates is associated with a large number
632 of assumptions (detailed in the corresponding sections of the Supplementary Information), and as such,
633 care must be taken in the interpretation of estimates farther into the future, as the uncertainty
634 associated with the numerous sub-models that go into these estimates increases in time.

635 For practical purposes, our transmission model has made a large number of simplifying assumptions.
636 Key among these is the exclusion of movement between locations (e.g., importation) and the absence of
637 age structure and mixing within location (e.g., we assume a well-mixed population). It is clear that there
638 are large, super-spreader-like events that have occurred throughout the COVID-19 pandemic, and our
639 current model is unable to fully capture these dynamics within our predictions. Another important
640 assumption to note is that of the relationship between pneumonia seasonality and SARS-CoV-2
641 seasonality. To date, across both the northern and southern hemisphere, there is a strong association
642 between COVID-19 cases and deaths and general seasonal patterns of pneumonia deaths (SI Section
643 3.5). Our predictions through the end of 2020 are immensely influenced by the assumption that this
644 relationship will maintain through the year and that SARS-CoV-2 seasonality will be well approximated
645 by pneumonia seasonality. While we assess this assumption to the extent possible (see Supplementary
646 Information), we have not yet experienced a full year of SARS-CoV-2 transmission, and as such cannot
647 yet know if this assumption is valid.

648 Finally, the model presented herein is not the first model our team has developed to predict current
649 and future transmission of SARS-CoV-2. As the outbreak has progressed, we have attempted to adapt

650 our modeling framework to both the changing epidemiological landscape as well as the increase in data
651 that could be useful to inform a model⁴⁹. Changes in the dynamics of the outbreak overwhelmed both
652 the initial purpose and some key assumptions of our first model, requiring evolution in our approach.
653 While the current SEIR formulation is a more flexible framework (and thus less likely to need to be
654 wholly reconfigured as the outbreak progresses further), we fully expect the need to adapt our model to
655 accommodate future shifts in patterns of SARS-CoV-2 transmission. Incorporating movement within and
656 without locations is one example, but resolving our model at finer spatial scales as well as accounting for
657 differential exposure and treatment rates across sexes and races are other dimensions of transmission
658 modelling we currently do not account for but expect will be necessary additions in the coming months.
659 As we have done before, we will continually adapt, update, and improve our model based on need and
660 predictive validity.

661

662 **Data availability statement**

663 All estimates can be further explored through our customized online data visualization tools
664 (<https://covid19.healthdata.org/united-states-of-america>). The findings of this study are supported by data
665 available in public online repositories, data publicly available upon request of the data provider, and
666 data not publicly available owing to restrictions by the data provider. Non-publicly available data were
667 used under license for the current study but may be available from the authors upon reasonable request
668 and with permission of the data provider. Detailed tables and figures of data sources and availability can
669 be found in SI Figures 1-4, and SI Tables 1-11. All maps presented in this study are generated by the
670 authors using RStudio (R Version 3.6.3) and no permissions are required to publish them. Administrative
671 boundaries were retrieved from the Database of Global Administrative Areas (GADM). Land cover was
672 retrieved from the online Data Pool, courtesy of the NASA EOSDIS Land Processes Distributed Active

673 Archive Center (LP DAAC), USGS/Earth Resources Observation and Science (EROS) Center, Sioux Falls,
674 South Dakota. Populations were retrieved from WorldPop (<https://www.worldpop.org>).

675

676 Code availability statement

677 Our study follows the Guidelines for Accurate and Transparent Health Estimate Reporting (GATHER;
678 Supplementary Information). All code used for these analyses is publicly available online
679 (<http://github.com/ihmeuw/>).

680

681 Methods References

682 45. Global Burden of Disease Collaborative Network. *Global Burden of Disease Study 2015 (GBD 2015)*
683 *Covariates 1980-2015*. [http://ghdx.healthdata.org/record/ihme-data/gbd-2015-covariates-1980-](http://ghdx.healthdata.org/record/ihme-data/gbd-2015-covariates-1980-2015)
684 [2015](http://ghdx.healthdata.org/record/ihme-data/gbd-2015-covariates-1980-2015) (2016).

685 46. National Center for Health Statistics Mortality Surveillance System.

686 <https://gis.cdc.gov/grasp/fluview/mortality.html>.

687 47. Wang, X., Pan, Z. & Cheng, Z. Association between 2019-nCoV transmission and N95 respirator use.
688 *J. Hosp. Infect.* **105**, 104–105 (2020).

689 48. Pollán, M. *et al.* Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based
690 seroepidemiological study. *The Lancet* S0140673620314835 (2020) doi:10.1016/S0140-
691 6736(20)31483-5.

692 49. Murray, C. J. L. Op-Ed: My research team makes COVID-19 death projections. Here's why our
693 forecasts often change. *Los Angeles Times* (2020)

694

695 Acknowledgments

696 We thank the various Departments of Health and frontline health professionals who are not only
697 responding to this epidemic daily, but also provide the necessary data to inform this work – IHME wishes
698 to warmly acknowledge the support of these and others
699 (<http://www.healthdata.org/covid/acknowledgements>) who have made our COVID-19 estimation
700 efforts possible. This work was supported by the Bill & Melinda Gates Foundation, as well as funding
701 from the state of Washington and the National Science Foundation (2031096). We also extend a note of
702 particular thanks to John Stanton and Julie Nordstrom for their generous support.

703 Competing interests

704 This study was funded by the Bill & Melinda Gates Foundation. The funders of the study had no role in
705 study design, data collection, data analysis, data interpretation, writing of the final report, or decision to
706 publish. The corresponding author had full access to all of the data in the study and had final
707 responsibility for the decision to submit for publication.

708 Additional information

709 Supplementary Information is available for this paper: Supplementary Text on data and methods,
710 Supplementary Model descriptions, Supplementary References, Supplementary Figures 1-4, and
711 Supplementary Tables 1-11.

712

713 Extended Data Figure Legends

714 **EDF 1.** Estimated daily COVID-19 death rate (per 100,000 population) by state for three scenarios.

715 The inset map displays the estimated peak in daily deaths from COVID-19 death per 100,000 population by state
716 between 04 July and 31 December. The light yellow background separates the observed and predicted part of the
717 time series, before and after 04 July. The dashed vertical line identifies 03 November 2020. The red line is the
718 “mandates easing” scenario, the purple line the “plausible reference” scenario, and the green line the “universal
719 mask” scenario. Numbers are the means and uncertainty interval (UI) for the plausible reference scenario on dates
720 highlighted. State panels are ordered by decreasing population size. Two-letter state abbreviations are provided in
721 panels and the inset map. An asterisk next to state abbreviation indicates a state with one or more urban
722 agglomerations exceeding two million persons. State panels are scaled to accommodate the state with the highest
723 value (WA here), ranging from zero to 7.2. This map was generated with RStudio (R Version 3.6.3).

724 **EDF 2.** Estimated total hospital beds needed for COVID-19 patients by state from 01 February to 31
725 December, 2020 for three scenarios.

726 The inset map displays the estimated peak number of all COVID-19 beds above capacity by state between 04 July
727 and 31 December. The light yellow background separates the observed and predicted part of the time series,
728 before and after 04 July. The dashed vertical line identifies 03 November 2020. The purple line shows the time
729 trend in estimated total hospital beds needed for COVID-19 patients under the “plausible reference” scenario; the
730 horizontal red line identifies estimated total COVID-19 bed capacity for each state. Numbers are the means and
731 uncertainty interval (UI) for the plausible reference scenario on dates highlighted. State panels are ordered by
732 decreasing population size. Two-letter state abbreviations are provided in panels and the inset map. An asterisk
733 next to state abbreviation indicates a state with one or more urban agglomerations exceeding two million persons.
734 State panels are scaled to accommodate the state with the most available all COVID beds (TX here), ranging from
735 zero to 30,000. This map was generated with RStudio (R Version 3.6.3).

736 **EDF 3.** Estimated total ICU beds needed for COVID-19 patients by state from 01 February to 31
737 December 2020, for three scenarios.

738 The inset map displays the estimated peak number of all ICU COVID-19 beds above capacity by state between 04
739 July and 31 December. The light yellow background separates the observed and predicted part of the time series,
740 before and after 04 July. The dashed vertical line identifies 03 November 2020. The purple line shows the time
741 trend in estimated total ICU beds needed for COVID-19 patients under the “plausible reference” scenario; the
742 horizontal red line identifies estimated COVID-19 ICU bed capacity for each state. Numbers are the means and
743 uncertainty interval (UI) for the plausible reference scenario on dates highlighted. State panels are ordered by
744 decreasing population size. Two-letter state abbreviations are provided in panels and the inset map. An asterisk
745 next to state abbreviation indicates a state with one or more urban agglomerations exceeding two million persons.
746 State panels are scaled to accommodate the state with the most ICU COVID beds needed (NY here), ranging from
747 zero to 6,300. This map was generated with RStudio (R Version 3.6.3).

748 **EDF 4.** Estimated cumulative deaths from COVID-19 per 100,000 population from 01 February to 31
749 December 2020, by state, for three scenarios.

750 The inset map displays the cumulative deaths under the “plausible reference” scenario on 31 December 2020. The
751 light yellow background separates the observed and predicted part of the time series, before and after 04 July. The
752 dashed vertical line identifies 03 November 2020. The red line represents the estimated time trend for deaths in
753 the “mandates easing” scenario, the purple line the “plausible reference” scenario, and the green line the
754 “universal mask” scenario. Numbers are the means and uncertainty interval (UI) for the plausible reference
755 scenario on dates highlighted. State panels are ordered by decreasing population size. Two-letter state

756 abbreviations are provided in panels and the inset map. An asterisk next to state abbreviation indicates a state
757 with one or more urban agglomerations exceeding two million persons. State panels are scaled to accommodate
758 the state with the highest value (MA here), ranging from zero to 500 deaths per 100,000. This map was generated
759 with RStudio (R Version 3.6.3).

760 **EDF 5.** Estimated cumulative infections from SARS-CoV-2 from 01 February to 31 December 2020, by
761 state, for three scenarios.

762 The inset map displays the cumulative infections under the “plausible reference” scenario on 31 December 2020.
763 The light yellow background separates the observed and predicted part of the time series, before and after 04 July.
764 The dashed vertical line identifies 03 November 2020. The red line represents the estimated time trend for
765 infections in the “mandates easing” scenario, the purple line the “plausible reference” scenario, and the green line
766 the “universal mask” scenario. Numbers are the means and uncertainty interval (UI) for the plausible reference
767 scenario on dates highlighted. State panels are ordered by decreasing population size. Two-letter state
768 abbreviations are provided in panels and the inset map. An asterisk next to state abbreviation indicates a state
769 with one or more urban agglomerations exceeding two million persons. State panels are scaled to accommodate
770 the state with the highest value (CA here), ranging from zero to 14,000,000. This map was generated with RStudio
771 (R Version 3.6.3).

772 **EDF 6.** Estimated cumulative SARS-CoV-2 infection rate (per 100,000 population) by state for three
773 scenarios.

774 The inset map displays the estimated peak in cumulative infections from COVID-19 per 100,000 population by
775 state between 04 July and 31 December. The light yellow background separates the observed and predicted part of
776 the time series, before and after 04 July. The dashed vertical line identifies 03 November 2020. The red is the
777 “mandates easing” scenario, the purple line the “plausible reference” scenario, and green line the “universal
778 mask” scenario. Numbers are the means and uncertainty interval (UI) for the plausible reference scenario on dates
779 highlighted. State panels are ordered by decreasing population size. Two-letter state abbreviations are provided in
780 panels and the inset map. An asterisk next to state abbreviation indicates a state with one or more urban
781 agglomerations exceeding two million persons. State panels are scaled to accommodate the state with the highest
782 value (MA here), ranging from zero to 60,000. This map was generated with RStudio (R Version 3.6.3).

783 **EDF 7.** Estimated daily infections from SARS-CoV-2 from 01 February to 31 December 2020 by state
784 for three scenarios.

785 The inset map displays the daily infections under the “plausible reference” scenario on 31 December 2020. The
786 light yellow background separates the observed and predicted part of the time series, before and after 04 July. The
787 dashed vertical line identifies 03 November 2020. The red line represents the estimated time trend for daily
788 infections in the “mandates easing” scenario, the purple line the “plausible reference” scenario, and the green line
789 the “universal mask” scenario. Numbers are the means and uncertainty interval (UI) for the plausible reference
790 scenario on dates highlighted. State panels are ordered by decreasing population size. Two-letter state
791 abbreviations are provided in panels and the inset map. An asterisk next to state abbreviation indicates a state
792 with one or more urban agglomerations exceeding two million persons. State panels are scaled to accommodate
793 the state with the highest value (CA here), ranging from zero to 350,000. This map was generated with RStudio (R
794 Version 3.6.3).

795 **EDF 8.** Estimated daily SARS-CoV-2 infection rate (per 100,000 population) by state for three scenarios.

796 The inset map displays the estimated peak in daily infections from COVID-19 per 100,000 population by state
797 between 04 July and 31 December. The light yellow background separates the observed and predicted part of the
798 time series, before and after 04 July. The dashed vertical line identifies 03 November 2020. The red is the

799 “mandates easing” scenario, the purple line the “plausible reference” scenario, and green line the “universal
800 mask” scenario. Numbers are the means and uncertainty interval (UI) for the plausible reference scenario on dates
801 highlighted. State panels are ordered by decreasing population size. Two-letter state abbreviations are provided in
802 panels and the inset map. An asterisk next to state abbreviation indicates a state with one or more urban
803 agglomerations exceeding two million persons. State panels are scaled to accommodate the state with the highest
804 value (WA here), ranging from zero to 900. This map was generated with RStudio (R Version 3.6.3).

805 **EDF 9.** Modeled SARS-CoV-2 infection prediction totals compared with survey-derived seroprevalence
806 rates in select locations.

807 Fig. 1 Number of social distancing mandates by state in the US on a timeline starting on
808 01 February 2020 through to July 04 2020. States are ordered by decreasing population
809 size on the y-axis.




810

811

812 **Fig. 2 Cumulative deaths from 01 February to 31 December 2020.**


813 The inset map displays the cumulative deaths under the “plausible reference” scenario on 31 December 2020. A
 814 light yellow background separates the observed and predicted part of the time series, before and after 04 July. The
 815 dashed vertical line is 03 November. The red line is the “mandates easing” scenario, the purple line the “plausible
 816 reference” scenario, and green line the “universal mask” scenario. Numbers are the means and UIs for the
 817 plausible reference scenario on dates highlighted. The UIs are not shown for “mandates easing” and mask use
 818 scenario for clarity. State panels are ordered by decreasing population size. Two-letter state abbreviations are
 819 provided in panels and the inset map. An asterisk next to state abbreviation indicates a state with one or more
 820 urban agglomerations exceeding two million persons. State panels are scaled to accommodate the state with the
 821 highest value (CA here), ranging from zero to 68,000 cumulative deaths. This map was generated with RStudio (R
 822 Version 3.6.3).



823

824 **Fig. 3 Daily deaths from 01 February to 31 December 2020.**


825 The inset map displays the daily deaths under the “plausible reference” scenario on 31 December 2020. A light
 826 yellow background separates the observed and predicted part of the time series, before and after 04 July. The
 827 dashed vertical line is 03 November. The red line is the “mandates easing” scenario, the purple line the “plausible
 828 reference” scenario, and the green line the “universal mask” scenario. Numbers are the means and UIs for the
 829 plausible reference scenario on dates highlighted. The UIs are not shown for the “mandates easing” and “universal
 830 mask” scenarios for clarity. State panels are ordered by decreasing population size. Two-letter state abbreviations
 831 are provided in panels and the inset map. An asterisk next to state abbreviation indicates a state with one or more
 832 urban agglomerations exceeding two million persons. State panels are scaled to accommodate the state with the
 833 highest value (CA here), ranging from zero to 2,500 daily deaths. This map was generated with RStudio (R Version
 834 3.6.3).



835

836 Fig. 4 Time series for values of $R_{\text{effective}}$ by state in the US. Inset maps display the value
 837 of $R_{\text{effective}}$ on 03 November and 31 December 2020; time series of $R_{\text{effective}}$ are
 838 presented for each state as separate panels.


839 Time series for values of $R_{\text{effective}}$ by state in the US. Inset maps display the value of $R_{\text{effective}}$ on 03 November and 31
 840 December 2020; time series of $R_{\text{effective}}$ are presented for each state as separate panels. A light yellow background
 841 separates the observed and predicted part of the time series, before and after 04 July. The dashed vertical line is
 842 03 November. The red line is the “mandates easing” scenario, the purple line the “plausible reference” scenario,
 843 and green line the “universal mask” scenario. The UIs are not shown for “mandates easing” and mask use scenario
 844 for clarity. State panels are ordered by decreasing population size. Two-letter state abbreviations are provided in
 845 panels and the inset maps. An asterisk next to state abbreviation indicates a state with one or more urban
 846 agglomerations exceeding two million persons. For legibility purposes, the y-axes of the state panels go from 0.25
 847 to 2 and the x-axes go from 01 March to 31 December. These maps were generated with RStudio (R Version 3.6.3).



848

849 **EDF 1. Estimated daily COVID-19 death rate (per 100,000 population) by state for three**
 850 **scenarios.**


851 The inset map displays the estimated peak in daily deaths from COVID-19 death per 100,000 population by state
 852 between 04 July and 31 December. The light yellow background separates the observed and predicted part of the
 853 time series, before and after 04 July. The dashed vertical line identifies 03 November 2020. The red line is the
 854 “mandates easing” scenario, the purple line the “plausible reference” scenario, and the green line the “universal
 855 mask” scenario. Numbers are the means and uncertainty interval (UI) for the plausible reference scenario on dates
 856 highlighted. State panels are ordered by decreasing population size. Two-letter state abbreviations are provided in
 857 panels and the inset map. An asterisk next to state abbreviation indicates a state with one or more urban
 858 agglomerations exceeding two million persons. State panels are scaled to accommodate the state with the highest
 859 value (WA here), ranging from zero to 7.2. This map was generated with RStudio (R Version 3.6.3).



860

861 **EDF 2. Estimated total hospital beds needed for COVID-19 patients by state from 01**
 862 **February to 31 December 2020 for three scenarios.**


863 The inset map displays the estimated peak number of all COVID-19 beds above capacity by state between 04 July
 864 and 31 December. The light yellow background separates the observed and predicted part of the time series,
 865 before and after 04 July. The dashed vertical line identifies 03 November 2020. The purple line shows the time
 866 trend in estimated total hospital beds needed for COVID-19 patients under the “plausible reference” scenario; the
 867 horizontal red line identifies estimated total COVID-19 bed capacity for each state. Numbers are the mean and
 868 uncertainty interval (UI) for the plausible reference scenario on dates highlighted. State panels are ordered by
 869 decreasing population size. Two-letter state abbreviations are provided in panels and the inset map. An asterisk
 870 next to state abbreviation indicates a state with one or more urban agglomerations exceeding two million persons.
 871 State panels are scaled to accommodate the state with the most available all COVID beds (TX here), ranging from
 872 zero to 30,000. This map was generated with RStudio (R Version 3.6.3).



873

874 **EDF 3. Estimated total ICU beds needed for COVID-19 patients by state from 01**
 875 **February to 31 December 2020 for three scenarios.**


876 The inset map displays the estimated peak number of all ICU COVID-19 beds above capacity by state between 04
 877 July and 31 December. The light yellow background separates the observed and predicted part of the time series,
 878 before and after 04 July. The dashed vertical line identifies 03 November 2020. The purple line shows the time
 879 trend in estimated total ICU beds needed for COVID-19 patients under the “plausible reference” scenario; the
 880 horizontal red line identifies estimated COVID-19 ICU bed capacity for each state. Numbers are the mean and
 881 uncertainty interval (UI) for the plausible reference scenario on dates highlighted. State panels are ordered by
 882 decreasing population size. Two-letter state abbreviations are provided in panels and the inset map. An asterisk
 883 next to state abbreviation indicates a state with one or more urban agglomerations exceeding two million persons.
 884 State panels are scaled to accommodate the state with the most ICU COVID beds needed (NY here), ranging from
 885 zero to 6,300. This map was generated with RStudio (R Version 3.6.3).



886

887 **EDF 4. Estimated cumulative deaths from COVID-19 per 100,000 population from 01**
 888 **February to 31 December 2020 by state for three scenarios.**


889 The inset map displays the cumulative deaths under the “plausible reference” scenario on 31 December 2020. The
 890 light yellow background separates the observed and predicted part of the time series, before and after 04 July. The
 891 dashed vertical line identifies 03 November 2020. The red line represents the estimated time trend for deaths in
 892 the “mandates easing” scenario, the purple line the “plausible reference” scenario, and the green line the
 893 “universal mask” scenario. Numbers are the mean and uncertainty interval (UI) for the plausible reference scenario
 894 on dates highlighted. State panels are ordered by decreasing population size. Two-letter state abbreviations are
 895 provided in panels and the inset map. An asterisk next to state abbreviation indicates a state with one or more
 896 urban agglomerations exceeding two million persons. State panels are scaled to accommodate the state with the
 897 highest value (MA here), ranging from zero to 500 deaths per 100,000. This map was generated with RStudio (R
 898 Version 3.6.3).



899

900 **EDF 5. Estimated cumulative infections from SARS-CoV-2 from 01 February to 31**
 901 **December 2020 by state for three scenarios.**

902 The inset map displays the cumulative infections under the “plausible reference” scenario on 31 December 2020.
 903 The light yellow background separates the observed and predicted part of the time series, before and after 04 July.
 904 The dashed vertical line identifies 03 November 2020. The red line represents the estimated time trend for
 905 infections in the “mandates easing” scenario, the purple line the “plausible reference” scenario, and the green line
 906 the “universal mask” scenario. Numbers are the mean and uncertainty interval (UI) for the plausible reference
 907 scenario on dates highlighted. State panels are ordered by decreasing population size. Two-letter state
 908 abbreviations are provided in panels and the inset map. An asterisk next to state abbreviation indicates a state
 909 with one or more urban agglomerations exceeding two million persons. State panels are scaled to accommodate
 910 the state with the highest value (CA here), ranging from zero to 14,000,000. This map was generated with RStudio
 911 (R Version 3.6.3).




912

913

914 **EDF 6. Estimated cumulative SARS-CoV-2 infection rate (per 100,000 population) by**
 915 **state for three scenarios.**


916 The inset map displays the estimated peak in cumulative infections from COVID-19 per 100,000 population by
 917 state between 04 July and 31 December 31. The light yellow background separates the observed and predicted
 918 part of the time series, before and after 04 July. The dashed vertical line identifies 03 November 2020. The red line
 919 is the “mandates easing” scenario, the purple line the “plausible reference” scenario, and green line the “universal
 920 mask” scenario. Numbers are the means and uncertainty interval (UI) for the plausible reference scenario on dates
 921 highlighted. State panels are ordered by decreasing population size. Two-letter state abbreviations are provided in
 922 panels and the inset map. An asterisk next to state abbreviation indicates a state with one or more urban
 923 agglomerations exceeding two million persons. State panels are scaled to accommodate the state with the highest
 924 value (MA here), ranging from zero to 60,000. This map was generated with RStudio (R Version 3.6.3).



925

926 **EDF 7. Estimated daily infections from SARS-CoV-2 from 01 February to 31 December**
 927 **2020 by state for three scenarios**


928 The inset map displays the daily infections under the “plausible reference” scenario on 31 December 2020. The
 929 light yellow background separates the observed and predicted part of the time series, before and after 04 July. The
 930 dashed vertical line identifies 03 November 2020. The red line represents the estimated time trend for daily
 931 infections in the “mandates easing” scenario, the purple line the “plausible reference” scenario, and the green line
 932 the “universal mask” scenario. Numbers are the mean and uncertainty interval (UI) for the plausible reference
 933 scenario on dates highlighted. State panels are ordered by decreasing population size. Two-letter state
 934 abbreviations are provided in panels and the inset map. An asterisk next to state abbreviation indicates a state
 935 with one or more urban agglomerations exceeding two million persons. State panels are scaled to accommodate
 936 the state with the highest value (CA here), ranging from zero to 350,000. This map was generated with RStudio (R
 937 Version 3.6.3).



938


939 **EDF 8. Estimated daily SARS-CoV-2 infection rate (per 100,000 population) by state for**
 940 **three scenarios**

941 The inset map displays the estimated peak in daily infections from COVID-19 per 100,000 population by state
 942 between 04 July and 31 December. The light yellow background separates the observed and predicted part of the
 943 time series, before and after 04 July. The dashed vertical line identifies 03 November 2020. The red is the
 944 “mandates easing” scenario, the purple line the “plausible reference” scenario, and green line the “universal
 945 mask” scenario. Numbers are the means and uncertainty interval (UI) for the plausible reference scenario on dates
 946 highlighted. State panels are ordered by decreasing population size. Two-letter state abbreviations are provided in
 947 panels and the inset map. An asterisk next to state abbreviation indicates a state with one or more urban
 948 agglomerations exceeding two million persons. State panels are scaled to accommodate the state with the highest
 949 value (WA here), ranging from zero to 900. This map was generated with RStudio (R Version 3.6.3).



950

951 **EDF 9. Modeled SARS-CoV-2 infection prediction totals compared with survey-derived**
952 **seroprevalence rates in select locations**



953

954

955

956
957
958

Table 1. Cumulative deaths 04 July 2020 through 31 December 2020, maximum estimated daily deaths per million population, date of maximum daily deaths, and estimated $R_{\text{effective}}$ on 31 December 2020 for three scenarios

Location	"Mandates easing" scenario (SDM are removed and not reinstated)				"Reference" scenario (SDM imposed at daily death rate threshold of 8/million population)				"Universal mask use" scenario (95% of population wears masks and SDM re-imposed at daily death rate threshold of 8/million)			
	Cumulative deaths through 31 December 2020	Maximum estimated daily deaths per million	Date of maximum daily deaths	Estimated $R_{\text{effective}}$ on 31 December 2020	Cumulative deaths through 31 December 2020	Maximum estimated daily deaths per million	Date of maximum daily deaths	Estimated $R_{\text{effective}}$ on 31 December 2020	Cumulative deaths through 31 December 2020	Maximum estimated daily deaths per million	Date of maximum daily deaths	Estimated $R_{\text{effective}}$ on 31 December 2020
United States of America	430494 (288,046 - 649,582)	22.6 (9.4 - 42.1)	12/31/20	NA	294,565 (233,885 - 398,397)	5.6 (2.7 - 10.9)	12/5/20	NA	191,771 (175,160 - 223,377)	3.1 (1.4 - 6.5)	12/31/20	NA
California	65408 (29,525 - 146,665)	56.4 (15.7 - 135.1)	12/31/20	0.98 (0.65 - 1.15)	37,016 (21,755 - 73,145)	17.2 (6.0 - 46.2)	12/5/20	0.77 (0.68 - 0.81)	20,900 (15,189 - 33,133)	10.3 (3.6 - 27.5)	12/31/20	0.60 (0.55 - 0.64)
Florida	57685 (24,841 - 116,664)	32.1 (11.4 - 60.8)	12/27/20	0.90 (0.73 - 0.99)	18,868 (12,371 - 34,415)	10.4 (4.1 - 27.1)	10/3/20	1.07 (0.95 - 1.17)	15,335 (10,655 - 28,367)	6.9 (2.6 - 19.7)	12/31/20	1.00 (0.87 - 1.14)
Texas	43336 (20,081 - 86,964)	33.5 (11.6 - 66.5)	12/31/20	0.96 (0.76 - 1.08)	24,687 (13,871 - 47,796)	12.6 (4.7 - 30.9)	11/24/20	0.85 (0.76 - 0.90)	10,038 (7,776 - 14,920)	4.1 (1.9 - 9.0)	12/31/20	1.09 (0.94 - 1.27)
New York	33462 (32,770 - 34,377)	2.6 (1.3 - 4.9)	12/31/20	1.22 (1.04 - 1.45)	33,462 (32,770 - 34,377)	2.6 (1.3 - 4.9)	12/31/20	1.22 (1.04 - 1.45)	32,440 (32,202 - 32,746)	1.0 (0.9 - 1.1)	7/4/20	1.08 (0.95 - 1.24)
Massachusetts	30990 (20,155 - 43,981)	55.9 (29.6 - 90.6)	12/20/20	0.80 (0.63 - 0.94)	13,223 (11,236 - 17,357)	12.1 (5.4 - 28.8)	10/17/20	1.17 (1.07 - 1.22)	12,794 (10,761 - 17,887)	15.6 (5.7 - 42.2)	12/23/20	0.54 (0.45 - 0.62)
New Jersey	18731 (17,314 - 21,245)	7.7 (3.5 - 17.0)	12/31/20	1.21 (1.04 - 1.43)	18,731 (17,314 - 21,245)	7.7 (3.5 - 17.0)	12/31/20	1.21 (1.04 - 1.43)	16,787 (16,296 - 17,502)	4.0 (3.6 - 4.6)	7/4/20	1.16 (1.02 - 1.33)
Virginia	18687 (6,815 - 40,765)	49.1 (13.8 - 98.1)	12/31/20	0.93 (0.65 - 1.17)	8,508 (4,226 - 19,351)	13.8 (3.2 - 44.9)	11/17/20	0.90 (0.79 - 0.95)	4,860 (3,003 - 10,307)	9.7 (1.8 - 36.9)	12/31/20	0.63 (0.54 - 0.68)
Pennsylvania	18089 (10,377 - 44,570)	26.1 (5.5 - 88.1)	12/31/20	1.14 (0.82 - 1.40)	15,913 (9,900 - 35,021)	15.2 (3.4 - 57.3)	12/17/20	0.69 (0.57 - 0.75)	9,378 (8,158 - 12,926)	3.2 (1.0 - 11.2)	12/31/20	1.17 (1.01 - 1.39)
Washington	13715 (5,491 - 29,757)	67.1 (19.9 - 136.1)	12/31/20	0.96 (0.64 - 1.17)	6,803 (3,690 - 13,342)	16.2 (5.5 - 41.5)	11/30/20	0.86 (0.75 - 0.91)	2,474 (1,979 - 3,323)	5.4 (2.0 - 12.3)	12/31/20	1.22 (1.04 - 1.45)
Arizona	11928 (6,927 - 22,146)	33.5 (11.9 - 76.3)	12/31/20	1.07 (0.87 - 1.25)	8,819 (5,580 - 15,392)	13.2 (5.7 - 30.0)	12/4/20	0.79 (0.71 - 0.84)	4,249 (3,464 - 5,605)	6.2 (4.2 - 9.3)	7/15/20	1.09 (0.93 - 1.28)
Illinois	11032 (9,198 - 14,450)	5.8 (2.3 - 13.7)	12/31/20	1.14 (0.99 - 1.33)	11,032 (9,198 - 14,450)	5.8 (2.3 - 13.7)	12/31/20	1.14 (0.99 - 1.33)	8,336 (7,939 - 8,893)	2.6 (2.1 - 3.1)	7/4/20	0.98 (0.88 - 1.09)
Ohio	10045 (4,849 - 29,965)	12.6 (1.6 - 51.9)	12/31/20	1.10 (0.89 - 1.30)	10,037 (4,849 - 29,965)	12.3 (1.6 - 50.6)	12/30/20	0.64 (0.51 - 0.70)	4,053 (3,604 - 5,020)	2.4 (1.6 - 3.5)	7/18/20	1.01 (0.88 - 1.18)
Alabama	9540 (4,408 - 18,994)	42.0 (15.8 - 86.2)	12/31/20	0.98 (0.77 - 1.19)	5,706 (2,987 - 11,537)	12.5 (4.1 - 32.4)	11/21/20	0.96 (0.87 - 1.01)	1,852 (1,489 - 2,590)	3.5 (2.3 - 5.4)	7/18/20	1.12 (1.00 - 1.27)
South Carolina	9412 (4,064 - 19,281)	28.5 (9.6 - 58.3)	12/31/20	0.98 (0.82 - 1.13)	5,121 (2,590 - 10,405)	10.4 (3.2 - 28.1)	11/8/20	0.95 (0.83 - 1.01)	1,838 (1,329 - 2,936)	3.9 (2.4 - 6.0)	7/19/20	1.08 (0.97 - 1.22)
Michigan	8221 (7,177 - 11,999)	3.7 (1.0 - 17.1)	12/31/20	1.09 (0.96 - 1.27)	8,221 (7,177 - 11,999)	3.7 (1.0 - 17.1)	12/31/20	1.09 (0.96 - 1.27)	6,889 (6,691 - 7,297)	1.2 (0.9 - 1.5)	7/14/20	0.94 (0.82 - 1.12)
Louisiana	7059 (4,670 - 11,999)	23.3 (5.7 - 66.5)	12/31/20	1.14 (0.87 - 1.41)	6,720 (4,591 - 11,999)	16.0 (3.8 - 41.5)	12/22/20	0.76 (0.64 - 0.88)	4,064 (3,754 - 4,633)	3.6 (2.3 - 5.5)	7/16/20	1.14 (0.99 - 1.32)

medRxiv preprint doi: <https://doi.org/10.1101/2020.07.12.20151191>; this version posted July 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Location	"Mandates easing" scenario (SDM are removed and not reinstated)				"Reference" scenario (SDM imposed at daily death rate threshold of 8/million population)				"Universal mask use" scenario (95% of population wears masks and SDM re-imposed at daily death rate threshold of 8/million)			
	Cumulative deaths through 31 December 2020	Maximum estimated daily deaths per million	Date of maximum daily deaths	Estimated R _{effective} on 31 December 2020	Cumulative deaths through 31 December 2020	Maximum estimated daily deaths per million	Date of maximum daily deaths	Estimated R _{effective} on 31 December 2020	Cumulative deaths through 31 December 2020	Maximum estimated daily deaths per million	Date of maximum daily deaths	Estimated R _{effective} on 31 December 2020
	12,576)	66.0)	20	1.39)	11,496)	45.8)		0.81)				
Maryland	5012 (4,291 - 6,616)	7.5 (3.4 - 18.3)	12/31/20	1.17 (1.01 - 1.38)	5,012 (4,291 - 6,616)	7.5 (3.4 - 18.3)	12/31/20	1.17 (1.01 - 1.38)	3,754 (3,625 - 3,960)	1.9 (1.6 - 2.1)	7/4/20	1.04 (0.94 - 1.17)
Connecticut	5010 (4,671 - 5,915)	2.7 (0.8 - 9.1)	12/31/20	1.10 (0.98 - 1.28)	5,010 (4,671 - 5,915)	2.7 (0.8 - 9.1)	12/31/20	1.10 (0.98 - 1.28)	4,629 (4,536 - 4,798)	1.7 (1.4 - 2.0)	7/4/20	0.96 (0.85 - 1.11)
Georgia	4970 (3,528 - 9,578)	3.9 (0.6 - 16.8)	12/31/20	1.15 (1.00 - 1.35)	4,970 (3,528 - 9,578)	3.9 (0.6 - 16.8)	12/31/20	1.15 (1.00 - 1.35)	3,521 (3,206 - 4,143)	1.9 (1.4 - 2.4)	7/4/20	1.03 (0.90 - 1.18)
North Carolina	4521 (2,471 - 11,537)	8.7 (2.0 - 33.3)	12/31/20	1.17 (1.00 - 1.40)	4,521 (2,471 - 11,537)	8.7 (2.0 - 33.3)	12/31/20	0.64 (0.56 - 0.70)	1,974 (1,737 - 2,499)	1.2 (1.2 - 1.2)	7/4/20	1.07 (0.94 - 1.23)
Indiana	4371 (3,605 - 5,904)	5.0 (2.2 - 12.4)	12/31/20	1.14 (1.00 - 1.32)	4,371 (3,605 - 5,904)	5.0 (2.2 - 12.4)	12/31/20	1.14 (1.00 - 1.32)	3,025 (2,902 - 3,199)	1.8 (1.6 - 2.0)	7/4/20	0.94 (0.85 - 1.04)
Tennessee	4038 (1,420 - 10,235)	11.7 (1.7 - 40.1)	12/31/20	1.12 (0.95 - 1.32)	4,038 (1,420 - 10,235)	11.7 (1.7 - 40.1)	12/31/20	0.70 (0.60 - 0.75)	1,087 (861 - 1,565)	1.7 (1.0 - 2.8)	7/17/20	1.08 (0.98 - 1.16)
Nevada	3738 (1,039 - 11,987)	26.7 (3.2 - 80.1)	12/31/20	1.07 (0.73 - 1.36)	2,750 (909 - 8,884)	13.6 (1.5 - 54.0)	12/8/20	0.76 (0.57 - 0.83)	846 (665 - 1,452)	1.3 (0.6 - 2.6)	7/18/20	1.14 (0.99 - 1.36)
Mississippi	3702 (2,275 - 7,113)	12.9 (4.0 - 34.0)	12/31/20	1.07 (0.92 - 1.24)	3,674 (2,264 - 7,046)	11.7 (3.7 - 32.3)	12/27/20	0.70 (0.60 - 0.75)	1,798 (1,531 - 2,302)	5.0 (3.4 - 7.6)	7/18/20	1.01 (0.91 - 1.15)
Missouri	2470 (1,487 - 5,199)	4.4 (0.7 - 18.2)	12/31/20	1.16 (1.01 - 1.36)	2,470 (1,487 - 5,199)	4.4 (0.7 - 18.2)	12/31/20	1.16 (1.01 - 1.36)	1,452 (1,278 - 1,744)	1.4 (0.9 - 2.1)	7/11/20	1.01 (0.89 - 1.15)
Colorado	2280 (1,812 - 4,656)	2.7 (0.2 - 15.8)	12/31/20	1.18 (0.99 - 1.41)	2,280 (1,812 - 4,656)	2.7 (0.2 - 15.8)	12/31/20	1.18 (0.99 - 1.41)	1,855 (1,761 - 2,092)	0.7 (0.5 - 1.1)	7/4/20	1.01 (0.82 - 1.23)
Oregon	2277 (651 - 8,715)	24.8 (3.1 - 107.1)	12/31/20	1.20 (0.84 - 1.45)	2,142 (635 - 8,215)	19.0 (2.5 - 89.0)	12/26/20	0.73 (0.60 - 0.79)	422 (326 - 619)	1.1 (0.3 - 2.9)	12/31/20	1.21 (1.01 - 1.49)
Wisconsin	2216 (1,344 - 4,966)	5.0 (1.2 - 19.1)	12/31/20	1.15 (1.00 - 1.34)	2,216 (1,344 - 4,966)	5.0 (1.2 - 19.1)	12/31/20	1.15 (1.00 - 1.34)	1,107 (1,004 - 1,308)	1.1 (0.7 - 1.6)	7/17/20	0.99 (0.89 - 1.12)
Minnesota	2202 (1,847 - 3,507)	1.5 (1.2 - 1.7)	7/5/20	1.11 (1.00 - 1.28)	2,202 (1,847 - 3,507)	1.5 (1.2 - 1.7)	7/5/20	1.11 (1.00 - 1.28)	1,788 (1,706 - 1,926)	1.5 (1.2 - 1.7)	7/5/20	0.90 (0.79 - 1.06)
Kentucky	1944 (920 - 5,652)	6.1 (0.9 - 25.1)	12/31/20	1.11 (0.95 - 1.29)	1,944 (920 - 5,652)	6.1 (0.9 - 25.1)	12/31/20	1.11 (0.95 - 1.29)	867 (716 - 1,250)	1.0 (0.5 - 1.8)	7/19/20	1.02 (0.90 - 1.18)
New Mexico	1930 (694 - 7,359)	18.7 (0.9 - 82.3)	12/31/20	1.17 (0.80 - 1.47)	1,829 (684 - 6,791)	14.6 (0.7 - 67.9)	12/24/20	0.68 (0.48 - 0.75)	724 (602 - 1,039)	1.9 (0.9 - 3.6)	7/13/20	1.11 (0.90 - 1.34)
Kansas	1619 (516 - 5,697)	14.2 (1.5 - 60.5)	12/31/20	1.16 (0.91 - 1.41)	1,619 (516 - 5,697)	14.2 (1.5 - 60.5)	12/31/20	0.65 (0.51 - 0.71)	400 (338 - 524)	0.9 (0.5 - 1.4)	7/18/20	1.15 (1.03 - 1.28)
Rhode Island	1604 (1,304 - 2,231)	12.4 (4.8 - 31.5)	12/31/20	1.20 (1.04 - 1.41)	1,604 (1,304 - 2,231)	12.4 (4.8 - 31.5)	12/31/20	0.56 (0.48 - 0.61)	1,193 (1,118 - 1,314)	5.0 (4.3 - 5.8)	7/4/20	1.14 (1.02 - 1.29)
New Hampshire	1506 (625 - 4,212)	23.3 (3.3 - 80.0)	12/31/20	1.12 (0.83 - 1.38)	1,303 (594 - 3,484)	14.3 (2.0 - 55.3)	12/17/20	0.69 (0.56 - 0.75)	579 (467 - 841)	2.1 (2.1 - 2.1)	7/4/20	1.15 (1.01 - 1.36)
Arkansas	1232 (459 - 3,495)	5.6 (0.2 - 25.4)	12/31/20	1.14 (1.00 - 1.31)	1,232 (459 - 3,495)	5.6 (0.2 - 25.4)	12/31/20	1.14 (1.00 - 1.31)	476 (377 - 675)	1.7 (1.3 - 2.3)	7/4/20	1.06 (0.91 - 1.16)

medRxiv preprint doi: <https://doi.org/10.1101/2020.07.12.20151191>; this version posted July 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Location	"Mandates easing" scenario (SDM are removed and not reinstated)				"Reference" scenario (SDM imposed at daily death rate threshold of 8/million population)				"Universal mask use" scenario (95% of population wears masks and SDM re-imposed at daily death rate threshold of 8/million)			
	Cumulative deaths through 31 December 2020	Maximum estimated daily deaths per million	Date of maximum daily deaths	Estimated R _{effective} on 31 December 2020	Cumulative deaths through 31 December 2020	Maximum estimated daily deaths per million	Date of maximum daily deaths	Estimated R _{effective} on 31 December 2020	Cumulative deaths through 31 December 2020	Maximum estimated daily deaths per million	Date of maximum daily deaths	Estimated R _{effective} on 31 December 2020
Utah	1163 (427 - 3,705)	11.9 (2.0 - 48.4)	12/31/20	1.19 (0.94 - 1.47)	1,163 (427 - 3,705)	11.9 (2.0 - 48.4)	12/31/20	0.53 (0.40 - 0.59)	268 (230 - 339)	0.7 (0.5 - 0.8)	7/4/20	1.19 (1.05 - 1.33)
Nebraska	1068 (478 - 2,743)	9.9 (1.2 - 37.8)	12/31/20	1.15 (0.99 - 1.36)	1,068 (478 - 2,743)	9.9 (1.2 - 37.8)	12/31/20	0.61 (0.53 - 0.66)	436 (371 - 564)	1.6 (1.2 - 2.2)	7/4/20	1.04 (0.89 - 1.19)
Iowa	889 (815 - 1,057)	0.9 (0.7 - 1.0)	7/4/20	1.24	889 (815 - 1,057)	0.9 (0.7 - 1.0)	7/4/20	1.05 (0.92 - 1.24)	813 (788 - 851)	0.9 (0.7 - 1.0)	7/4/20	0.82 (0.68 - 0.98)
Oklahoma	888 (589 - 1,862)	3.2 (0.7 - 12.5)	12/31/20	1.19 (1.01 - 1.42)	888 (589 - 1,862)	3.2 (0.7 - 12.5)	12/31/20	1.19 (1.01 - 1.42)	522 (480 - 600)	0.6 (0.4 - 0.8)	7/11/20	1.00 (0.87 - 1.16)
District of Columbia	759 (649 - 1,122)	5.1 (1.1 - 20.2)	12/31/20	1.13 (0.99 - 1.32)	759 (649 - 1,122)	5.1 (1.1 - 20.2)	12/31/20	1.13 (0.99 - 1.32)	633 (609 - 679)	3.0 (2.5 - 3.5)	7/4/20	1.00 (0.88 - 1.18)
Delaware	668 (592 - 876)	1.9 (0.5 - 6.7)	12/31/20	1.04 (0.91 - 1.22)	668 (592 - 876)	1.9 (0.5 - 6.7)	12/31/20	1.04 (0.91 - 1.22)	587 (565 - 625)	1.5 (1.1 - 1.9)	7/4/20	0.86 (0.74 - 1.03)
South Dakota	428 (162 - 1,194)	8.6 (0.8 - 35.0)	12/31/20	1.19 (1.02 - 1.40)	428 (162 - 1,194)	8.6 (0.8 - 35.0)	12/31/20	0.52 (0.43 - 0.57)	165 (130 - 227)	1.6 (0.8 - 2.9)	7/17/20	1.05 (0.89 - 1.21)
Idaho	150 (107 - 305)	0.8 (0.0 - 4.5)	12/31/20	1.27 (1.09 - 1.53)	150 (107 - 305)	0.8 (0.0 - 4.5)	12/31/20	1.27 (1.09 - 1.53)	107 (102 - 118)	0.2 (0.1 - 0.3)	7/9/20	1.14 (0.99 - 1.26)
Maine	132 (117 - 175)	0.2 (0.1 - 0.3)	7/7/20	1.24	132 (117 - 175)	0.2 (0.1 - 0.3)	7/7/20	1.09 (0.99 - 1.24)	119 (115 - 127)	0.2 (0.1 - 0.3)	7/7/20	1.00 (0.83 - 1.09)
West Virginia	129 (105 - 190)	0.2 (0.0 - 0.9)	12/31/20	1.13 (1.01 - 1.31)	129 (105 - 190)	0.2 (0.0 - 0.9)	12/31/20	1.13 (1.01 - 1.31)	108 (102 - 117)	0.2 (0.1 - 0.3)	7/5/20	1.02 (0.85 - 1.12)
North Dakota	103 (92 - 125)	0.3 (0.2 - 0.5)	7/11/20	0.89 (0.68 - 1.08)	103 (92 - 125)	0.3 (0.2 - 0.5)	7/11/20	0.89 (0.68 - 1.08)	94 (90 - 100)	0.3 (0.2 - 0.5)	7/11/20	0.68 (0.50 - 0.83)
Vermont	64 (58 - 81)	0.4 (0.0 - 2.2)	12/31/20	1.40 (1.14 - 1.78)	64 (58 - 81)	0.4 (0.0 - 2.2)	12/31/20	1.40 (1.14 - 1.78)	59 (58 - 60)	0.0 (0.0 - 0.1)	7/4/20	1.29 (1.12 - 1.51)
Montana	22 (21 - 24)	0.1 (0.0 - 0.2)	7/4/20	0.90 (0.53 - 1.20)	22 (21 - 24)	0.1 (0.0 - 0.2)	7/4/20	0.90 (0.53 - 1.20)	22 (21 - 24)	0.1 (0.0 - 0.2)	7/4/20	0.72 (0.40 - 1.04)
Wyoming	18 (18 - 19)	0.1 (0.0 - 0.1)	7/4/20	0.76 (0.36 - 1.12)	18 (18 - 19)	0.1 (0.0 - 0.1)	7/4/20	0.76 (0.36 - 1.12)	18 (18 - 19)	0.1 (0.0 - 0.1)	7/4/20	0.57 (0.26 - 0.88)
Hawaii	18 (17 - 19)	0.0 (0.0 - 0.1)	7/4/20	0.97 (0.55 - 1.23)	18 (17 - 19)	0.0 (0.0 - 0.1)	7/4/20	0.70 (0.46 - 0.79)	18 (17 - 19)	0.0 (0.0 - 0.1)	7/4/20	1.00 (0.71 - 1.28)
Alaska	14 (13 - 15)	0.1 (0.1 - 0.2)	7/4/20	0.87 (0.64 - 1.16)	14 (13 - 15)	0.1 (0.1 - 0.2)	7/4/20	0.87 (0.64 - 1.16)	14 (13 - 15)	0.1 (0.1 - 0.2)	7/4/20	0.73 (0.51 - 1.00)

medRxiv preprint doi: <https://doi.org/10.1101/2020.07.12.20151191>; this version posted July 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.